OncoVista Innovative Therapies Inc
OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatmen… Read more
OncoVista Innovative Therapies Inc (OVIT) - Net Assets
Latest net assets as of September 2015: $-6.59 Million USD
Based on the latest financial reports, OncoVista Innovative Therapies Inc (OVIT) has net assets worth $-6.59 Million USD as of September 2015.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($61.27K) and total liabilities ($6.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.59 Million |
| % of Total Assets | -10755.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | -441.91% |
| 10-Year Change | N/A |
| Growth Volatility | 9.34 |
OncoVista Innovative Therapies Inc - Net Assets Trend (2000–2014)
This chart illustrates how OncoVista Innovative Therapies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OncoVista Innovative Therapies Inc (2000–2014)
The table below shows the annual net assets of OncoVista Innovative Therapies Inc from 2000 to 2014.
| Year | Net Assets | Change |
|---|---|---|
| 2014-12-31 | $-5.66 Million | -81.53% |
| 2013-12-31 | $-3.12 Million | -85.78% |
| 2012-12-31 | $-1.68 Million | -1253.91% |
| 2011-12-31 | $-124.03K | -107.49% |
| 2010-12-31 | $1.66 Million | +114.72% |
| 2009-12-31 | $-11.25 Million | -34.78% |
| 2008-12-31 | $-8.35 Million | -109.05% |
| 2007-12-31 | $-3.99 Million | -120.69% |
| 2006-12-31 | $-1.81 Million | -14.93% |
| 2005-12-31 | $-1.57 Million | -21.05% |
| 2004-12-31 | $-1.30 Million | -28.49% |
| 2003-12-31 | $-1.01 Million | -43.75% |
| 2002-12-31 | $-704.00K | -1035.48% |
| 2001-12-31 | $-62.00K | -126.16% |
| 2000-12-31 | $237.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to OncoVista Innovative Therapies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2590251300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2014)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $22.01K | % |
| Other Components | $20.22 Million | % |
| Total Equity | $-5.66 Million | 100.00% |
OncoVista Innovative Therapies Inc Competitors by Market Cap
The table below lists competitors of OncoVista Innovative Therapies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Everlert Inc
PINK:EVLI
|
$1.00 |
|
Green Mountain Devel
PINK:GMND
|
$1.00 |
|
Bourque Indts Inc
PINK:BORK
|
$1.00 |
|
Crumbs Bake Shop Inc
PINK:CRMBQ
|
$1.00 |
|
GeckoSystems International Corp
PINK:GOSY
|
$1.00 |
|
Resgreen Group International Inc
PINK:RGGI
|
$0.99 |
|
Health-Chem Corporation
PINK:HCLC
|
$0.99 |
|
Technology Solutions Co
PINK:TSCC
|
$0.99 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OncoVista Innovative Therapies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2013 to 2014, total equity changed from -3,119,762 to -5,663,160, a change of -2,543,398.
- Net loss of 2,544,393 reduced equity.
- Other factors increased equity by 995.
Equity Change Factors (2013 to 2014)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.54 Million | -44.93% |
| Other Changes | $995.00 | +0.02% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares OncoVista Innovative Therapies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-0.08 | $0.00 | x |
| 2005-12-31 | $-0.09 | $0.00 | x |
| 2007-12-31 | $-0.23 | $0.00 | x |
| 2008-12-31 | $-0.46 | $0.00 | x |
| 2009-12-31 | $-0.61 | $0.00 | x |
| 2010-12-31 | $0.08 | $0.00 | x |
| 2011-12-31 | $-0.01 | $0.00 | x |
| 2012-12-31 | $-0.08 | $0.00 | x |
| 2013-12-31 | $-0.14 | $0.00 | x |
| 2014-12-31 | $-0.26 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OncoVista Innovative Therapies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (61.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | -568.76% | 1.33x | 0.00x | $-313.56K |
| 2005 | 0.00% | -184.58% | 1.89x | 0.00x | $-116.27K |
| 2007 | 0.00% | -307.65% | 0.37x | 0.00x | $-5.20 Million |
| 2008 | 0.00% | -1486.52% | 0.91x | 0.00x | $-6.65 Million |
| 2009 | 0.00% | -486.57% | 2.40x | 0.00x | $-3.66 Million |
| 2010 | 609.99% | 0.00% | 0.00x | 2.14x | $9.94 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.01 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.46 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.14 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.98 Million |
Industry Comparison
This section compares OncoVista Innovative Therapies Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OncoVista Innovative Therapies Inc (OVIT) | $-6.59 Million | 0.00% | N/A | $1.00 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |